Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20230822002
- Term of Validity
- 22 August 2023 - 21 August 2025
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- UK SME has developed a brain monitoring system for neurological and psychiatric conditions using digital biomarkers for CNS (central nervous system) drug trials. This is captured via their EEG (Electroencephalogram) headset and gamification therapy app which helps increase trial efficacy and cost-effectiveness. The SME is seeking partnerships with pharmaceutical companies interested in digital therapeutics and EEG biomarkers for CNS trials via a commercial agreement with technical assistance.
- Full Description
-
The UK medical device SME who specialises in medical therapeutics and aids has developed a unique AI driven neurofeedback monitoring system for patients suffering with psychiatric and neurological conditions such as Alzheimer’s disease, autism, schizophrenia and dementia.
The system’s AI algorithms integrate brain regions and brainwaves to provide detailed and unique mapping which are bespoke to trial design. It integrates LOREATA (low resolution electromagnetic tomographic analysis) to provide in depth brain details which cannot be achieved with normal EEG processing.
The neurofeedback system is an AI-powered system with a home-based 16-electrode EEG (Electroencephalogram) headset. It provides comprehensive brain wave data to customise gaming therapies for cognitive function normalisation based on the science called "Neuroplasticity".
The SME is keen to establish partnership with pharmaceuticals and pharma suppliers for preclinical and phase 1 trials of CNS drugs especially associated with cognitive parameters (e.g. alzheimers, schizophrenia, autism etc,) to help improve the device’s function and achieve validation on the benefits and advantages being claimed. This is envisaged via a strategic commercial agreement with technical assistance. - Advantages and Innovations
- Digital therapeutics and biomarkers combined are a powerful tool for enhancing CNS trials. They provide a comprehensive overview of the trial process, allowing for more accurate and efficient data collection along with cost-effectiveness.
- Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
- Pharmaceutical companies and suppliers keen on digital therapeutics and EEG (electroencephalogram) biomarkers for CNS (central nervous system) clinical trials. The company is keen to partner especially with those who are involved in cognitive parameters. (e.g. Alzheimers, Schizophrenia and Autism etc)
- Type and Size of Partner
- Big company
- SME 50 - 249
- R&D Institution
- Other
- SME 11-49
- University
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001012 - Medical Research
- 06001014 - Neurology, Brain Research
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 005001008 - Diagnostic test products and equipment
- 05003001 - Therapeutic services
- 05003006 - Other therapeutic (including defibrillators)
- 05001001 - Diagnostic services
- 05001007 - Other diagnostic
- Sector Groups Involved
- Health
- Targeted countries
- All countries